Key result
Microinfusion single-use mechanical systems were described for antitumor drug therapy and pain relief in patients with malignant tumors, with no quantitative outcomes reported in the abstract.
Why the study?
Intravenous antitumor infusions can cause phlebitis, extravasation, and venous access difficulties, necessitating rational approaches to ensure patient safety and maintain quality of life during therapy.
Observational
The use of microinfusion single-use mechanical systems and venous ports may improve quality of life and ensure safe, continuous intravenous access for patients receiving antitumor therapy.
Recently due to significant successes in drug therapy of malignant tumors, the question of quality of life of patients has become more important. Cyclical drug treatment implies intravenous infusion of antitumor agents. Complications associated with this type of therapy include phlebitis and extravasation and, in some cases, lead to full obliteration of vessel lumen and vast skin and hypoderm necrosis. Multiple venous punctions can with time lead to significant technical difficulties in accessing the vein and limit the continuation of therapy. This drives the necessity to search for rational approaches to patient safety during both outpatient and inpatient antitumor drug treatment. To solve this problem, fully implanted venous port systems were developed and implemented in clinical practice which provide organization of aseptic continuous venous access, as well as infusion pumps (for independent prolonged intravenous therapy). Use of these devices allows for continuity and cycling of treatment process, significantly improves patients' quality of life by not limiting daily activities.In the article we present our experience of using microinfusion single-use mechanical systems for antitumor drug therapy and relief of intense pain syndrome in patients with malignant disorders of hematopoietic tissue and solid tumors.
No takes yet. Share an insight, caveat, or question.
Ryabukhina et al. (2022) conducted an observational in Malignant disorders of hematopoietic tissue and solid tumors. Microinfusion single-use mechanical systems was evaluated. Microinfusion single-use mechanical systems were described for antitumor drug therapy and pain relief in patients with malignant tumors, with no quantitative outcomes reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: